Aetna
Aetna Aetna
Specialty Pharmacy Clinical Policy Bulletins
Aetna Non-Medicare Prescription Drug Plan
Subject: Specialty Quantity Limit Jynarque 2571-H P2022

Drug
JYNARQUE  (tolvaptan)


Policy:

      I.  PROGRAM DESCRIPTION

          The standard limit is designed to allow a quantity sufficient for the most
          common uses of the medication. The recommended dosing parameters
          for all FDA-approved indications fall within the standard limits. Coverage
          of an additional quantity may be reviewed on a case-by-case basis upon
          request.

 

    II.  COVERED QUANTITIES

     Medication

  Standard Limit

            FDA-recommended dosing

  Jynarque Carton 15mg-
  15mg tablets

  56 per 28 days

  Initial dose is 60mg orally daily (45mg on
  waking and 15mg 8 hours later). Titrate to
  90mg daily (60mg on waking and 30mg 8
  hours later) and then to 120mg daily (90mg on
  waking and 30mg 8 hours later) if tolerated
  with at least weekly intervals between
  titrations. Patients may down-titrate based on
  tolerability.

 

  Co-Administration with Moderate CYP 3A
  Inhibitors:
  Reduce dose per below. Consider further
  reductions if patient cannot tolerate the
  reduced dose.
  •  120mg daily: reduce to 60mg daily (45mg
      on waking and 15mg 8 hours later)
  •  90mg daily: reduce to 45mg daily (30mg on
      waking and 15mg 8 hours later)
  •  60mg daily: reduce to 30mg daily (15mg on
     waking and 15mg 8 hours later)

  Jynarque Carton 30mg-
  15mg tablets

  56 per 28 days

  Jynarque Carton 45mg-
  15mg tablets

  56 per 28 days

  Jynarque Carton 60mg-
  30mg tablets

  56 per 28 days

  Jynarque Carton 90mg-
  30mg tablets

  56 per 28 days

  Jynarque 30mg tablets
  (30 count bottle)

  30 per 30 days

  Jynarque 15mg tablets
  (30 count bottle)

  60 per 30 days

 


Place of Service:

Outpatient

The above policy is based on the following references:
  1. Jynarque [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; October 2020.
Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

April 17, 2022
Aetna
Skip Past Footer Links
Company Information   |   Site Map Aetna.com Home   |   Help   |   Contact Us   |   Search
Web Privacy Statement   |   Legal Statement   |   Privacy Notices   |   Member Disclosure

Back to top